학술논문
Patient-reported outcome (PRO) measures at 12 months (12M) in a real-world cohort of people living with HIV (PLWH) with a high prevalence of comorbidities receiving bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in Europe, Canada, and Israel
Document Type
Journal
Author
Source
Subject
Language
English
ISSN
14681293